[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"icsi\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:icsi":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,81,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100628035","development-of-an-ai-platform-for-the-analysis-of-sperm-and-prediction-of-their-clinical-potential-100628035",false,"NCT07456397","Development of an AI Platform for the Analysis of Sperm and Prediction of Their Clinical Potential","Development and Validation of an Artificial Intelligence Platform for the Analysis of Sperm Samples and Prediction of Their Clinical Potential","Spermy01","Male participants:\n\nInclusion Criteria:\n\n* Ability to provide a semen sample via masturbation\n* Semen sample intended for use in an IVF\u002FICSI cycle\n\nExclusion Criteria:\n\n* Current diagnosis of a sexually transmitted infection (STI)\n* Previous diagnosis of hepatitis A, B, C, D, or HIV\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months\n\nFemale participants:\n\nInclusion Criteria:\n\n* Urdengoing an IVF\u002FICSI cycle with partner or donor semen\n\nExclusion Criteria:\n\n* Prior participation in this study\n* Participation in a clinical trial involving an intervention within the last 3 months","ALL","18 Years","60 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","Prospective, multicenter research study with a split-sample design on semen samples, without intervention, to develop an artificial intelligence platform for the analysis of sperm samples and prediction of their clinical potential, in 500 semen samples, in an in vitro study over 24 months.",[26,27,28,29,30],"Infertility (IVF Patients)","ICSI","IVF Outcomes","Male Infertility","Reproductive Issues","RECRUITING","2026-06-10",{"date":34,"type":35},"2026-06-12","ACTUAL",{"date":37,"type":35},"2026-03-18",{"date":39,"type":22},"2028-02",{"name":41,"class":42},"Fecundis Lab SL","OTHER",5,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":4},"100636796","comparison-of-two-types-of-calcium-ca-ionophore-treatments-for-oocyte-activation-in-cases-of-suboptimal-fertilization-potential-100636796","NCT07570342","Comparison of Two Types of Calcium (Ca²⁺) Ionophore Treatments for Oocyte Activation in Cases of Suboptimal Fertilization Potential","(Ca²⁺)","Inclusion Criteria:\n\n1. Patients undergoing assisted reproductive technology cycles when ICSI is indicated.\n2. Patients with a minimum of 3 MII oocytes after denudation.\n3. Maternal age 18-43 years old.\n4. PGT-A cycles with only trophectoderm biopsies on day 5\u002F6\u002F7.\n5. BMI\\\u003C35.\n6. Fresh and frozen immotile ejaculated sperm.\n7. Fresh and frozen TESE sperm (motile and immotile).\n8. Globozoospermia.\n\n10\\. Couples undergoing ICSI due to poor fertilization history (≤30%), or previous fertilization failure.\n\nExclusion Criteria:\n\n1. PGT-M\u002FSR cycles.\n2. Fresh and frozen motile ejaculated \u002F FNA sperm.\n3. IVF inseminated oocytes.",true,"FEMALE","43 Years",{"count":55,"type":22},20,"INTERVENTIONAL",[58],"NA","This study aims to investigate the effectiveness and safety of assisted oocyte activation (AOA) using Ca²⁺ ionophores in cases of total fertilization failure (TFF) due to oocyte activation deficiency (OAD). The study will be conducted in two phases: Phase I will compare the fertilization rates of oocytes exposed to two types of Ca²⁺ ionophore treatments- Ionomycin solution and commercially available CultActive-against a control group without calcium ionophore treatment. Phase II will assess whether an additional injection of CaCl2, prior to exposure to the chosen ionophore from Phase I, further improves fertilization outcomes. The goal is to identify the optimal AOA protocol for improving fertilization rates and to evaluate the safety and efficacy of this approach in relation to ploidy, with a focus on ensuring normal pre-implantation embryo development.",[27,61,29,62],"Testicular Sperm Extraction in Azoospermic Patients","PGT-A",[27,62,64,65,66,67,68,69,70],"artificial oocyte activation","AOA","calcium ionophore","ionomycin","TESE","Immotile sperm","Failed fertilization","NOT_YET_RECRUITING","2026-05-06",{"date":74,"type":35},"2026-05-11",{"date":76,"type":22},"2026-04-30",{"date":78,"type":22},"2026-12-31",{"name":80,"class":42},"ART Fertility Clinics LLC",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":51,"sex":52,"minAge":18,"maxAge":53,"enrollmentInfo":87,"targetDuration":4,"studyType":56,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100613719","impact-of-dry-vs-humidified-culture-conditions-on-blastocyst-development-and-aneuploidy-a-time-lapse-sibling-oocyte-study-100613719","NCT07270250","Impact of Dry vs Humidified Culture Conditions on Blastocyst Development and Aneuploidy: A Time-lapse Sibling Oocyte Study","Inclusion Criteria:\n\n* PGT-A cycles with more than at least 4 mature oocytes\n* ICSI\n* maternal age 18- 43 years old\n* PGT-A intended cycles with trophectoderm biopsies on day 5 \u002F6\u002F7\n* patients with more than 8 oocytes expected for ICSI\n* BMI \\\u003C35\n* fresh and frozen ejaculated sperm\n\nExclusion Criteria:\n\n* PGT-M \u002FPGT-SR cycles\n* fresh and frozen testicular sperm\n* IVF insemination\n* previous history of fertilization failure",{"count":88,"type":22},60,[58],"IVF incubators are essential for maintaining the micro-environment required for embryo development. Incubator technology has progressed from early humidified box systems to benchtop and now time-lapse platforms, driving the development of dry incubator chambers. Both humidified and dry systems have specific pros and cons. Evidence to date suggests that humidified chambers may support better blastocyst development in certain \"no-refresh\" continuous culture conditions, but current data are limited and study designs remain weak. This study aims to compare sibling oocytes cultured in dry versus humidified chambers within a GERI time-lapse incubator under continuous culture conditions, assessing effects on viability and developmental outcomes. Findings may inform optimal incubation strategies to improve IVF success rates while supporting uninterrupted workflows and potentially improving cost-benefit efficiency in the IVF laboratory.",[92,93,94,95,96,97,27],"Incubator Stay","Total Blastulation","Blastocyst Quality","Biopsy Rate","Fertilization Rate","Ploidy Rate",{"date":99,"type":35},"2026-05-07",{"date":101,"type":35},"2026-02-10",{"date":103,"type":22},"2027-12-31",{"name":80,"class":42},1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":56,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":105},"100600140","evaluating-the-utility-of-implementing-microfluids-for-sperm-preparation-compared-to-conventional-method-of-density-gradient-centrifugation-in-a-pgt-a-program-a-sibling-oocyte-study-100600140","NCT07093619","Evaluating the Utility of Implementing Microfluids for Sperm Preparation Compared to Conventional Method of Density Gradient Centrifugation in a PGT-A Program: a Sibling Oocyte Study","Inclusion Criteria:\n\n1. Women with at least 8 MII per cycle after denudation (AFC≥8).\n2. Women of all ages.\n3. All embryo qualities ≥BL3CC at the time of biopsy on day 5, 6 and\u002For 7.\n4. Fresh sperm used from ejaculate with a concentration ≥1 mill\u002Fml and ≥10% motility (A+B).\n5. Sperm samples with a minimum of 2 ml.\n\nExclusion Criteria:\n\n* Frozen oocytes samples with severe oligospermia (≤1mill\u002Fml).\n* PGT-M cases\n* Sperm with \\> 1M\u002Fml of round cells",{"count":113,"type":22},100,[58],"In assisted reproductive technology (ART), sperm preparation aims to select the most viable sperm for ICSI. Unlike conventional methods like density gradients or sperm washing, microfluidic techniques mimic natural selection in the female reproductive tract by using laminar flow without centrifugation, reducing the risk of DNA damage. This method isolates highly motile sperm while filtering out debris and immotile cells. Studies show that microfluidics improve embryo quality, increase pregnancy rates, and may lead to higher euploidy rates. Additional benefits include improved safety, scalability, and shorter preparation times.",[117,27,62],"Semen Analysis",[119,120,121,122,123,124],"IVF","Sperm Preparation","euploid","fertilization rate","blastulation rate","morphokinetics","2025-09-30",{"date":127,"type":35},"2025-10-02",{"date":129,"type":35},"2025-09-12",{"date":131,"type":22},"2026-12-30",{"name":80,"class":42}]